Respiratory syncytial virus infection in older adults: an under-recognized problem
- PMID: 25851217
- DOI: 10.1007/s40266-015-0258-9
Respiratory syncytial virus infection in older adults: an under-recognized problem
Abstract
Human respiratory syncytial virus (RSV) is an enveloped, single-stranded, negative-sense RNA virus and member of the Paramyxoviridae family of the genus Pneumovirus that was first reported as a major pathogen in pediatric populations. However, since its discovery, RSV has not infrequently been detected in adults. Reinfection occurs throughout life, with more severe disease occurring in older adults, immunocompromised patients, and those with underlying cardiopulmonary disease. Initially described as the cause of nursing home outbreaks of respiratory disease, there is a now significant body of literature describing the clinical importance of RSV in older adults in a multitude of settings including long-term care, adult daycares, and in community-dwelling adults. Moreover, recent reports from China and other countries emphasize that RSV is a global pathogen that will become increasingly important in developed nations with aging populations. Annual attack rates in the USA range from 2 to 10% in community-dwelling older adults and 5-10% in older adults living in congregate settings. Population-based calculations of the proportion of acute respiratory illnesses attributable to RSV estimate that 11,000 elderly persons die annually in the USA of illnesses related to RSV infection. Clinical manifestations of RSV infections are similar to that of other viral respiratory pathogens and include cough, nasal congestion, rhinorrhea, sore throat, and dyspnea. Lower respiratory tract disease is common and may result in respiratory failure (8-13%) or death (2-5%). Recent advances in molecular diagnostics have made it possible to rapidly identify RSV infection using nucleic acid amplification tests, although clinicians will need to suspect the diagnosis when viral activity is high. At the present time, treatment is supportive. Effective antiviral agents for the treatment and vaccines for prevention of RSV remain a significant unmet medical need in the older adult population.
Similar articles
-
Respiratory syncytial virus infections in adults: a narrative review.Lancet Respir Med. 2024 Oct;12(10):822-836. doi: 10.1016/S2213-2600(24)00255-8. Epub 2024 Sep 9. Lancet Respir Med. 2024. PMID: 39265602 Review.
-
Symptomatic respiratory syncytial virus infection in previously healthy young adults living in a crowded military environment.Clin Infect Dis. 2005 Aug 1;41(3):311-7. doi: 10.1086/431591. Epub 2005 Jun 29. Clin Infect Dis. 2005. PMID: 16007526
-
Respiratory syncytial virus infection in adults.Clin Microbiol Rev. 2000 Jul;13(3):371-84. doi: 10.1128/CMR.13.3.371. Clin Microbiol Rev. 2000. PMID: 10885982 Free PMC article. Review.
-
Respiratory syncytial virus infection in elderly adults.Med Mal Infect. 2018 Sep;48(6):377-382. doi: 10.1016/j.medmal.2018.01.008. Epub 2018 Mar 13. Med Mal Infect. 2018. PMID: 29548714 Review.
-
Clinical and epidemiologic features of respiratory syncytial virus.Curr Top Microbiol Immunol. 2013;372:39-57. doi: 10.1007/978-3-642-38919-1_2. Curr Top Microbiol Immunol. 2013. PMID: 24362683
Cited by
-
Pediatric human nose organoids demonstrate greater susceptibility, epithelial responses, and cytotoxicity than adults during RSV infection.bioRxiv [Preprint]. 2024 Feb 1:2024.02.01.578466. doi: 10.1101/2024.02.01.578466. bioRxiv. 2024. Update in: J Infect. 2024 Dec;89(6):106305. doi: 10.1016/j.jinf.2024.106305 PMID: 38352333 Free PMC article. Updated. Preprint.
-
Severe Morbidity and Mortality Associated With Respiratory Syncytial Virus Versus Influenza Infection in Hospitalized Older Adults.Clin Infect Dis. 2019 Jul 2;69(2):197-203. doi: 10.1093/cid/ciy991. Clin Infect Dis. 2019. PMID: 30452608 Free PMC article.
-
Luciferase-Based Biosensors in the Era of the COVID-19 Pandemic.ACS Nanosci Au. 2021 Aug 9;1(1):15-37. doi: 10.1021/acsnanoscienceau.1c00009. eCollection 2021 Dec 15. ACS Nanosci Au. 2021. PMID: 37579261 Free PMC article. Review.
-
Novel genetically-modified chimpanzee adenovirus and MVA-vectored respiratory syncytial virus vaccine safely boosts humoral and cellular immunity in healthy older adults.J Infect. 2019 May;78(5):382-392. doi: 10.1016/j.jinf.2019.02.003. Epub 2019 Feb 8. J Infect. 2019. PMID: 30742894 Free PMC article. Clinical Trial.
-
Innate immune responses in the ageing lung.Clin Exp Immunol. 2017 Jan;187(1):16-25. doi: 10.1111/cei.12881. Epub 2016 Nov 2. Clin Exp Immunol. 2017. PMID: 27711979 Free PMC article. Review.
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical